Explore

TrendlineTrendline
Circle Pharma Strengthens Leadership with New Chief Scientific Officer and Head of HR

Circle Pharma Strengthens Leadership with New Chief Scientific Officer and Head of HR

Circle Pharma Strengthens Leadership with New Chief Scientific Officer and Head of HR
Rapid ReadRapid Read
XYone Therapeutics Initiates First-in-Human Clinical Trial for Novel Cancer Drug XYA02

XYone Therapeutics Initiates First-in-Human Clinical Trial for Novel Cancer Drug XYA02

XYone Therapeutics, a clinical-stage biotechnology company based in greater Boston, MA, has announced that the first patient has been dosed in its first-in-human Phase 1b/2 clinical trial for XYA02 (also known as AT2021). XYA02 is a novel antibody-drug conjugate (ADC) specifically designed to target MUC1-C, a protein expressed across various solid tumors. The multicenter, open-label study aims to evaluate the safety and tolerability of XYA02, determine appropriate dose levels for future clinical development, and assess its pharmacokinetics, pharmacodynamics, and preliminary antitumor activity. The trial includes patients with advanced, relapsed, and/or refractory solid tumors, specifically non-small cell lung, ovarian, gastric/GEJ, and colorectal cancers. The U.S. Food and Drug Administration (FDA) has already granted XYA02 Orphan Drug Designation (ODD) for the treatment of pancreatic cancer and gastric cancer.
TrendlineTrendline
Executive Turnover Poses Significant Risk in Corporate Mergers and Acquisitions

Executive Turnover Poses Significant Risk in Corporate Mergers and Acquisitions

Executive Turnover Poses Significant Risk in Corporate Mergers and Acquisitions
Rapid ReadRapid Read
Link Cell Therapies Initiates Phase I Trial for Logic-Gated CAR-T Therapy in Kidney Cancer, Expands Series A Funding

Link Cell Therapies Initiates Phase I Trial for Logic-Gated CAR-T Therapy in Kidney Cancer, Expands Series A Funding

Link Cell Therapies, an oncology cell therapy company, has begun clinical dosing for its lead program, LNK001, a logic-gated CAR-T therapy, in a Phase I study for advanced clear cell renal cell carcinoma (RCC) at MD Anderson Cancer Center. LNK001 is designed to target both CAIX and ENPP3 antigens, which are highly expressed in most RCC tumors. This dual-targeting approach aims to overcome the limitations of conventional CAR-T cells that target only CAIX, which can cause on-target, off-tumor toxicity in healthy tissues. The company also announced an expansion of its Series A financing from $60 million to $90 million, with additional capital supporting the clinical and preclinical development of other logic-gated CAR-T programs. Furthermore, Link Cell Therapies has appointed Jie D'Elia, Ph.D., as Chief Executive Officer, and Friedrich Graf Finckenstein, M.D., as Chief Medical Officer, with co-founder Brian Slingerland transitioning to Executive Chair.
Rapid ReadRapid Read
Link Cell Therapies Initiates Phase I Trial for Kidney Cancer Treatment and Expands Series A Funding

Link Cell Therapies Initiates Phase I Trial for Kidney Cancer Treatment and Expands Series A Funding

Link Cell Therapies, an oncology cell therapy company, has initiated clinical dosing for its lead program, LNK001, a logic-gated CAR-T therapy for advanced clear cell renal cell carcinoma (RCC). The Phase I study is being conducted at MD Anderson Cancer Center. LNK001 is designed to target two antigens, CAIX and ENPP3, which are highly expressed in most RCC tumors, aiming to overcome the limitations of single-antigen CAR-T approaches that can cause toxicity in healthy tissues. The company also announced a $30 million expansion of its Series A financing, increasing the total to $90 million. This additional capital will support the clinical and preclinical development of further logic-gated CAR-T programs, including a second solid tumor indication in colorectal cancer, with a first-in-human trial planned for 2027. Additionally, Link Cell Therapies has appointed Jie D'Elia, Ph.D., as Chief Executive Officer and Friedrich Graf Finckenstein, M.D., as Chief Medical Officer, while co-founder Brian Slingerland tra...
TrendlineTrendline
Tempus AI Seeks Computational Biologist for Pharma R in Boston

Tempus AI Seeks Computational Biologist for Pharma R in Boston

Tempus AI Seeks Computational Biologist for Pharma R in Boston
VarietyVariety
Mattel Hires Condé Nast’s Roger Lynch as CEO, Ynon Kreiz to Exit for New Job

Mattel Hires Condé Nast’s Roger Lynch as CEO, Ynon Kreiz to Exit for New Job

Mattel is getting a new CEO: The toymaker and media company announced that Roger Lynch, who’s been chief exec of Condé Nast for more than seven years, will become its next CEO. Lynch will become chairman of Mattel effective Oct. 2 and will assume the role of CEO “effective on or before” Nov. 2. He […]
VarietyVariety
Naomi Bulochnikov-Paul Exits Disney TV for ‘New Opportunty’ After Eight Years as Head of Communications

Naomi Bulochnikov-Paul Exits Disney TV for ‘New Opportunty’ After Eight Years as Head of Communications

Naomi Bulochnikov-Paul is exiting Disney TV as head of communications after eight years. Bulochnikov-Paul has spent eight years at the company, most recently as executive vice president, communications, for Disney Entertainment Television. In a memo to staff she said she was exiting “to pursue a new opportunity.” Bulochnikov-Paul’s exit is the latest shift at Disney’s […]
TheStreetTheStreet
Citi delivers major verdict after Moderna’s remarkable 703% run

Citi delivers major verdict after Moderna’s remarkable 703% run

Moderna’s rally has priced in unrealistic expectations for its cancer drug sales.
TrendlineTrendline
Link Cell Therapies Initiates CAR-T Trial and Expands Series A Funding to $90 Million

Link Cell Therapies Initiates CAR-T Trial and Expands Series A Funding to $90 Million

Link Cell Therapies Initiates CAR-T Trial and Expands Series A Funding to $90 Million
TrendlineTrendline
Tolerance Bio Licenses Clinical-Stage Antibody TLB-33 from Tanabe Pharma to Expand Thymus-Focused Pipeline

Tolerance Bio Licenses Clinical-Stage Antibody TLB-33 from Tanabe Pharma to Expand Thymus-Focused Pipeline

Tolerance Bio Licenses Clinical-Stage Antibody TLB-33 from Tanabe Pharma to Expand Thymus-Focused Pipeline
TrendlineTrendline
Precede Biosciences Seeks Director for Precision Medicine and IVD Development

Precede Biosciences Seeks Director for Precision Medicine and IVD Development

Precede Biosciences Seeks Director for Precision Medicine and IVD Development